India, Aug. 3 -- Eisai, a leading global research and development-based pharmaceutical company headquartered in Japan, has announced the launch of Leqembi (lecanemab) for the treatment of early Alzheimer's disease in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO).

In India, LEQEMBI is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer's disease, marking the introduction of this first-of-its-kind Disease-Modifying Therapy (DMT) in the country's Alzheimer's disease treatment landscape.

The launch comes amid a growing dementia burden in India, driven by an ageing population, late diagnosis, and limited awareness.

According to estimates...